Comparing irinotecan/cisplatin with etoposide/cisplatin in patients with ED-SCLC: a meta-analysis of efficacy and toxicity

Authors
Category Structured summary of systematic reviews
JournalDatabase of Abstracts of Reviews of Effects (DARE)
Year 2013
CRD SUMMARY: The review concluded that irinotecan plus cisplatin did not lengthen overall survival or progression-free survival compared with etoposide plus cisplatin in patients with extensive-stage disease small cell lung cancer but the adverse events profile differs considerably. The uncertain quality of the evidence base and differences across studies limit the reliability of the authors' conclusions.
Epistemonikos ID: 34c097f7615808bb8da454e5225116cae3f25061
First added on: Feb 04, 2013